Batavia Biosciences has entered a collaboration with RocketVax, a subsidiary of Swiss Rockets AG, for the development of vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus. 
 
RocketVax is developing a promising second generation COVID-19 vaccine candidate, called RVX-13 which, instead of containing only one COVID-19 derived antigen, comprises all major immunogenic features of the SARS-CoV-2 virus. This unique technology aims at delivering a more efficacious vaccine and protect against all known variants of the SARS-CoV-2 virus.
 
“Batavia will collaborate with RocketVax to develop an innovative process able to rapidly deliver 1,000 doses of material for clinical trials,” said Chris Yallop, COO, Batavia Biosciences. “After successful completion, we will continue to scale-up and optimize the process for commercial scale.”
 
To ensure the vaccine is available as soon as possible and manufactured cost-effectively, Batavia will deploy its HIP-Vax highly intensified manufacturing technology to deliver a robust and scalable clinical process for RVX-13.
 
Natasa Cmiljanovic, executive board member, RocketVax, said, “The company and production headquarters of RocketVax are located in Switzerland. With Batavia, RocketVax will enter into its first partnership abroad in order to be able to implement the production capacity of the vaccine on an expanded scale. Further partnerships are being planned.”
 
Menzo Havenga, CEO, Batavia Biosciences, said, “The vaccine developed by RocketVax is totally unique and highly promising, giving broad protection against diverse virus strains. We are proud that we are selected to deliver the product for clinical studies using our HIP-Vax technology.”
 
RocketVax aims to start the phase I clinical trials in Q2-2022.